Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone
Authors
Keywords
-
Journal
Expert Review of Neurotherapeutics
Volume 21, Issue 9, Pages 1019-1033
Publisher
Informa UK Limited
Online
2021-09-16
DOI
10.1080/14737175.2021.1968298
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Opicapone: A Review in Parkinson’s Disease
- (2021) Lesley J. Scott CNS DRUGS
- Safety and efficacy of tolcapone in Parkinson’s disease: systematic review
- (2021) Carlo Alberto Artusi et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Istradefylline – a first generation adenosine A2A antagonist for the treatment of Parkinson’s disease
- (2021) Peter Jenner et al. Expert Review of Neurotherapeutics
- Non‐Motor Fluctuations in Parkinson's Disease: Validation of the Non‐Motor Fluctuation Assessment Questionnaire
- (2021) Galit Kleiner et al. MOVEMENT DISORDERS
- Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
- (2021) Mezin Öthman et al. Journal of Personalized Medicine
- Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
- (2020) Heinz Reichmann et al. Translational Neurodegeneration
- Opicapone and Levodopa-Carbidopa Intestinal Gel Infusion: The Way Forward Towards Cost Savings for the Healthcare Systems?
- (2020) Valentina Leta et al. Journal of Parkinsons Disease
- Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients With Motor Fluctuations
- (2020) Atsushi Takeda et al. MOVEMENT DISORDERS
- Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys
- (2020) Maria João Bonifácio et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease
- (2019) Constant V.M. Verschuur et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long‐term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open‐label extensions
- (2019) J. J. Ferreira et al. EUROPEAN JOURNAL OF NEUROLOGY
- Levodopa is the best symptomatic therapy for PD: Nothing more, nothing less
- (2019) C. Warren Olanow MOVEMENT DISORDERS
- Should there be less emphasis on levodopa‐induced dyskinesia in Parkinson's disease?
- (2019) K. Ray Chaudhuri et al. MOVEMENT DISORDERS
- The impact of levodopa therapy-induced complications on quality of life in Parkinson’s disease patients in Singapore
- (2019) Jonathan Wu et al. Scientific Reports
- The Movement Disorder Society Nonmotor Rating Scale: Initial Validation Study
- (2019) K. Ray Chaudhuri et al. MOVEMENT DISORDERS
- Safety Profile of Opicapone in the Management of Parkinson’s Disease
- (2019) Andrew Lees et al. Journal of Parkinsons Disease
- Motor complications in Parkinson's disease: 13‐year follow‐up of the CamPaIGN cohort
- (2019) Han‐Joon Kim et al. MOVEMENT DISORDERS
- Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease
- (2018) Lawrence W. Elmer et al. CNS DRUGS
- Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach
- (2018) Angelo Antonini et al. CURRENT MEDICAL RESEARCH AND OPINION
- Pain in Parkinson's disease: facts and uncertainties
- (2018) A. Antonini et al. EUROPEAN JOURNAL OF NEUROLOGY
- International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease
- (2018) Susan H. Fox et al. MOVEMENT DISORDERS
- Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease
- (2018) Joaquim J. Ferreira et al. NEUROLOGY
- Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial
- (2018) Regina Katzenschlager et al. LANCET NEUROLOGY
- Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine
- (2018) Margherita Fabbri et al. MOVEMENT DISORDERS
- Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson’s disease treated with L-DOPA
- (2017) Andrew J. Lees et al. Expert Review of Neurotherapeutics
- Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson’s disease treated with L-DOPA
- (2017) Andrew J. Lees et al. Expert Review of Neurotherapeutics
- Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations
- (2017) Andrew J. Lees et al. JAMA Neurology
- Factors associated with motor complications in Parkinson's disease
- (2017) Liis Kadastik-Eerme et al. Brain and Behavior
- Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial
- (2016) Joaquim J Ferreira et al. LANCET NEUROLOGY
- Risk and course of motor complications in a population-based incident Parkinson's disease cohort
- (2016) Anders Bjornestad et al. PARKINSONISM & RELATED DISORDERS
- Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat
- (2015) M J Bonifácio et al. BRITISH JOURNAL OF PHARMACOLOGY
- Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease
- (2015) Thomas Müller DRUGS
- Motor complications in an incident Parkinson's disease cohort
- (2015) N. W. Scott et al. EUROPEAN JOURNAL OF NEUROLOGY
- The “Gender Factor” in Wearing-Off among Patients with Parkinson’s Disease: A Post Hoc Analysis of DEEP Study
- (2015) Delia Colombo et al. TheScientificWorldJOURNAL
- Exploring Issues Around Wearing-off and Quality of Life: The OFF-PARK Survey of People with Parkinson’s Disease and their Care Partners
- (2015) Helen Matthews et al. Journal of Parkinsons Disease
- The “Gender Factor” in Wearing-Off among Patients with Parkinson’s Disease: A Post Hoc Analysis of DEEP Study
- (2015) Delia Colombo et al. Scientific World Journal
- Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations
- (2014) José-Francisco Rocha et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Medicinal Chemistry of Catechol O-Methyltransferase (COMT) Inhibitors and Their Therapeutic Utility
- (2014) László E. Kiss et al. JOURNAL OF MEDICINAL CHEMISTRY
- Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition
- (2014) Siegfried Muhlack et al. JOURNAL OF NEURAL TRANSMISSION
- Novel formulations and modes of delivery of levodopa
- (2014) Werner Poewe et al. MOVEMENT DISORDERS
- Improvingl-dopa therapy: The development of enzyme inhibitors
- (2014) Oscar S. Gershanik MOVEMENT DISORDERS
- Clinical spectrum of levodopa-induced complications
- (2014) Camila Catherine Aquino et al. MOVEMENT DISORDERS
- Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics
- (2014) Peter A. LeWitt MOVEMENT DISORDERS
- Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries
- (2014) Marlene C. Hechtner et al. PARKINSONISM & RELATED DISORDERS
- Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study
- (2013) C Warren Olanow et al. LANCET NEUROLOGY
- Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease
- (2013) C. Warren Olanow et al. MOVEMENT DISORDERS
- Nonmotor fluctuations in Parkinson disease: Severity and correlation with motor complications
- (2013) A. Storch et al. NEUROLOGY
- Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor
- (2013) M.J. Bonifácio et al. NEUROPHARMACOLOGY
- Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal delivery
- (2013) Thomas Müller et al. PARKINSONISM & RELATED DISORDERS
- Early DEtection of wEaring off in Parkinson disease: The DEEP study
- (2013) F. Stocchi et al. PARKINSONISM & RELATED DISORDERS
- Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects
- (2012) Luis Almeida et al. CLINICAL PHARMACOKINETICS
- Computation of the binding affinities of catechol-O-methyltransferase inhibitors: Multisubstate relative free energy calculations
- (2012) P. Nuno Palma et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- Continuous drug delivery in early- and late-stage Parkinson’s disease as a strategy for avoiding dyskinesia induction and expression
- (2011) P. Jenner et al. JOURNAL OF NEURAL TRANSMISSION
- Determination of minimal clinically important change in early and advanced Parkinson's disease
- (2011) Robert A. Hauser et al. MOVEMENT DISORDERS
- PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease
- (2011) Fabrizio Stocchi et al. MOVEMENT DISORDERS
- Extended-release pramipexole in advanced Parkinson disease: A randomized controlled trial
- (2011) A. H. V. Schapira et al. NEUROLOGY
- The economic burden of advanced Parkinson’s disease: an analysis of a UK patient dataset
- (2011) Leslie J. Findley et al. JOURNAL OF MEDICAL ECONOMICS
- Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study
- (2010) Fabrizio Stocchi et al. ANNALS OF NEUROLOGY
- When Do Levodopa Motor Fluctuations First Appear in Parkinson’s Disease
- (2010) Fabrizio Stocchi et al. EUROPEAN NEUROLOGY
- Discovery of a Long-Acting, Peripherally Selective Inhibitor of Catechol-O-methyltransferase
- (2010) László E. Kiss et al. JOURNAL OF MEDICINAL CHEMISTRY
- The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson’s disease
- (2010) Mark Stacy JOURNAL OF NEURAL TRANSMISSION
- Determinants of health-related quality of life in Parkinson’s disease: A systematic review
- (2010) Sze-Ee Soh et al. PARKINSONISM & RELATED DISORDERS
- Levodopa-related wearing-off in Parkinson's disease: identification and management
- (2009) Rajesh Pahwa et al. CURRENT MEDICAL RESEARCH AND OPINION
- Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily
- (2009) Mikko Kuoppamäki et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson’s disease: a long-term, retrospective analysis
- (2009) H. Nissinen et al. EUROPEAN JOURNAL OF NEUROLOGY
- Levodopa: Past, Present, and Future
- (2009) Robert A. Hauser EUROPEAN NEUROLOGY
- A reassessment of risks and benefits of dopamine agonists in Parkinson's disease
- (2009) Angelo Antonini et al. LANCET NEUROLOGY
- Pain intensity on and off levodopa in patients with Parkinson's disease
- (2009) Angelika Nebe et al. MOVEMENT DISORDERS
- Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease
- (2008) Andrew J. Lees CNS Neuroscience & Therapeutics
- Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
- Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease
- (2008) Robert A. Hauser et al. MOVEMENT DISORDERS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now